Phase I proof-of-concept multiple-dose trial of TT 401 in obese patients with or without type 2 diabetes mellitus.
Latest Information Update: 07 May 2013
Price :
$35 *
At a glance
- Drugs Pegapamodutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions
- 30 Apr 2013 Results published in Transition Therapeutics media release.
- 30 Apr 2013 Status changed from planning to completed, as reported in Transition Therapeutics media release.
- 20 Jun 2012 New trial record